Retinal Neurovascular Coupling in Patients Previously Infected With COVID-19
Medical University of Vienna
90 participants
Jul 26, 2021
OBSERVATIONAL
Conditions
Summary
The Study objective is to measure retinal neurovascular coupling and blood flow parameters in patients previously infected with COVID-19, long COVID-19 and healthy age- and sex- matched control subjects
Eligibility
Inclusion Criteria18
- Men and women aged over 18 years
- Non-smokers
- Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant
- No previous history of COVID-19 infection
- Negative testing for SARS-CoV-2 seroprevalence using nucleocapsid antibody tests
- Negative PCR test for SARS-CoV-2
- Normal ophthalmic findings, ametropy \< 6 Dpt.
- Men and women aged over 18 years
- Non-smokers
- History of COVID-19 infection (confirmed by a positive PCR test for SARS-CoV2 in the medical history) within the last 6 months
- Positive testing for SARS-CoV-2 seroprevalence using spike protein IgG antibody tests
- Negative PCR test for SARS-CoV-2
- Men and women aged over 18 years
- Non-smokers
- History of COVID-19 infection (confirmed by a positive PCR test for SARS-CoV2 in the medical history)
- Positive testing for SARS-CoV-2 seroprevalence
- Negative PCR test for SARS-CoV-2
- Long Covid according to the latest WHO-Guidelines
Exclusion Criteria27
- Any of the following will exclude a healthy control subject from the study:
- Symptoms of a clinically relevant illness in the 3 weeks before the first study day
- Presence or history of a severe medical condition as judged by the clinical investigator
- Participation in a clinical trial in the 3 weeks preceding the study
- Blood donation during the previous three weeks
- History or family history of epilepsy
- Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator
- Best corrected visual acuity \< 0.8 Snellen
- Pregnancy, planned pregnancy or lactatin
- History of epilepsia
- Any of the following will exclude a subject with history of COVID-19 infection from the study:
- Blood donation during the previous three weeks
- History or family history of epilepsy
- Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator
- Best corrected visual acuity \< 0.8 Snellen
- Ametropy \>6 Dpt
- Pregnancy, planned pregnancy or lactating
- History of epilepsia
- Any of the following will exclude a subject with long COVID-19 from the study:
- Blood donation during the previous three weeks
- History or family history of epilepsy
- Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator
- Best corrected visual acuity \< 0.8 Snellen
- Ametropy \>6 Dpt
- Pregnancy, planned pregnancy or lactating
- History of epilepsia
- Diabetes mellitus
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Retinal neurovascular coupling, Retinal vessel diameters and Retinal oxygen saturation will be assessed using the DVA
Retinal blood velocities and Retinal blood flow will be assessed using the FDOCT
Retinal nerve fiber layer thickness, Central retinal thickness and Retinal vessel density will be assessed using the OCT
Normalized blur and Relative flow volume will be assessed using the LSFG
Proteomics and Metabolites in Plasma, tear fluid and finger sweat will be assessed using a Blooddraw, filter paper and Schirmer-test
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05650905